Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07831369
PHASE2

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Sponsor: Inova Health Care Services

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas

Key Details

Gender

All

Age Range

18 Years - 98 Years

Study Type

INTERVENTIONAL

Enrollment

52

Start Date

2026-09-04

Completion Date

2030-12-30

Last Updated

2026-09-21

Healthy Volunteers

No

Interventions

DRUG

Valproic Acid (VPA)

Day 1 40mg/kg/dose PO BID and simvastatin at 40mg PO daily

DRUG

Irinotecan

D2 irinotecan 180mg/m2 IV and VPA 40mg/kg/dose PO BID, simvastatin at 40mg PO daily

DRUG

Simvastatin

Day3-21 Continuous simvastatin starting at 40mg daily PO

Locations (1)

Inova Schar Cancer

Fairfax, Virginia, United States